



Drug Utilization Review Board Meeting Minutes March 10, 2020

The Nebraska Drug Utilization (DUR) Board met March 10, 2020 at the Cornhusker Marriott on the 3rd Floor of the Convention Center in room Yankee Hill 3, Lincoln, NE.

DUR Board Members in attendance: Kevin Borchert, RP; Lynn Carlson, RP; Shana Castillo, RP; Eric Gall, RP; Bruce Houghton, MD; Roger Mattson, RP; Charlie Moore, RP; Kirk Muffly, MD; David Randolph, RP; Phil Vuchetich, RP; Robert Wergin, MD.
DUR Board Member not in attendance: Susan Howard, MD.

DHHS attendees: Carisa Schweitzer-Masek, Director of Population Health, Nebraska Medicaid and Long-Term Care; Leah Spencer, Program Specialist, R.N.

Contracted attendees:

Jessica Czechowski, RP, Magellan RX Management; Nikia Bennette-Carter, RP, Magellan Rx Management.

Jamie Benson, RP, Nebraska Total Care; Shannon Nelson, WellCare of Nebraska; Bernadette Ueda, RP, United Health Care.

Public visitors:

Berend Koops, Merck; Nancy Bell, Pfizer; Mike Frey, NNI; Joni Cover, Nebraska Pharmacists Association; Marcia Mueting, Nebraska Pharmacists Association; Brent Hildebrand; Gilead.

I. Call to Order:

The meeting was called to order by Carisa Schweitzer-Masek on March 10, 2020 at 6:30 pm CDT. Members and attendees were welcomed and asked to introduce themselves. Public attendees were directed to complete a sign-in sheet to be added to the meeting minutes. Carisa Schweitzer-Masek made know that meeting materials and the Open-Meetings Law were available.

II. Conflict of Interest

Carisa Schweitzer-Masek calls for declaration of conflicts of interest. None were declared.

III. Agenda approval

No changes were made to the March 10, 2020 meeting agenda as presented. A motion was made by Kirk Muffly and a second made by Robert Wergin to approve the agenda, which was approved unanimously.

IV. Meeting Minutes; July 9, 2019

A motion was made by Robert Wergin and a second by Phil Vuchetich to accept the July 9, 2019 minutes. Vote: Borchert- yes, Carlson-yes, Castillo-yes, Gall-yes, Houghton-yes, Mattson-abstain, Moore-abstain, Muffly-yes, Randolph-yes, Vuchetich-yes, Wergin-yes. Motion carried.

V. Update on Recommendations from July 2019 Meeting

Carisa Schweitzer-Masek provided information to inform that hepatitis C criteria changes were implemented as approved from the previous meeting. No further discussion.

VI. Special Topics

Carisa Schweitzer-Masek gave updates on legislative updates on the SUPPORT Act and drug utilization and NE SPA submission and approval.

A request was made for volunteers to review the NE DUR policy for updates and revisions. David Randolph and Roger Mattson volunteered to take on this assignment.

An update on a possible Request for Proposal for DUR vendor was made by Carisa Schweitzer-Masek.

Carisa Schweitzer-Masek asked the committee for recommendations on future required DUR meeting frequency. After discussion, a motion was made by Dave Randolph to keep meetings to six times annually and second made by Charlie Moore.

Vote: Borchert- yes, Carlson- yes, Castillo-yes, Gall-yes, Houghton-yes, Mattson-yes, Moore-yes, Muffly-no, Randolph-yes, Vuchetich-yes, Wergin-yes. Motion carried.

VII. Retrospective DUR

A motion was made by Kirk Muffly and a second made by Eric Gall to change current MME tapering schedule from every six (6) months to every three (3) months. The last taper was made to 200 MME on December 1, 2019. The new schedule would follow:

- June 1, 2020 150 MME
- September 1, 2020 120 MME
- December 1, 2020 90 MME

Votes: Borchert- no, Carlson- no, Castillo-yes, Gall-yes, Houghton-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes, Wergin-yes. Motion carried.

Carisa Schweitzer-Masek explained the benefit tiers for future Heritage Health Adult (HHA) eligibility. The committee is asked to bring to the next meeting any recommendations that would

encompass ideas of data for chronic/behavioral health conditions and medication utilization projects that could be used for this population. DHHS will bring data trends to the next meeting as well.

VIII. Prospective DUR

The SUPPORT Act was reviewed by Carisa Schweitzer-Masek related to anti-psychotic medications, specifically in children. An ask to board was made for recommendation guidance of a program/ methodology that could be used to monitor antipsychotic use in children. The board requested more information regarding this population and data. At the next meeting, DHHS will provide information that will provide useful data to assist in making recommendations.

IX. Special Requests from the State

Carisa Schweitzer-Mask noted that montelukast, which is a current PDL preferred medication at this time, has an FDA boxed warning regulated to neuropsychiatric event reported in patients taking montelukast. Discussion outlined recommendation of the committee regarding adding clinical criteria for medication use and mental health conditions. DHHS will provide more specific data to the committee to review for possible DUR recommendations.

A request was made by Carisa Schweitzer-Masek for recommendations related to COVID19 and pharmacy processes. Recommendations were made for temporary initiatives for member one-time early refill of medications which exclude refills for schedule II medications.

X. Future Meeting Dates

To be determined.

XI. Concerns & Comments

XII. Adjournment

A motion was made by Charlie Moore and a second by Bruce Houghton to adjourn the meeting. Vote: Borchert- yes, Carlson-yes, Castillo-yes, Gall-yes, Houghton-yes, Mattson- yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes, Wergin-yes. Motion carried and the meeting was adjourned at 8:30 pm.